Search Results - "BRUNETTO, Virginia L"

Phase III Trial of Doxorubicin Plus Cisplatin With or Without Paclitaxel Plus Filgrastim in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group Study by FLEMING, Gini F, BRUNETTO, Virginia L, CELLA, David, LOOK, Katherine Y, REID, Gary C, MUNKARAH, Adnan R, KLINE, Richard, BURGER, Robert A, GOODMAN, Annekathryn, BURKS, R. Tucker

“…To determine whether the addition of paclitaxel to doxorubicin plus cisplatin improves overall survival (OS) in women with advanced or recurrent endometrial…”
Get full text

Randomized Phase III Trial of Standard Timed Doxorubicin Plus Cisplatin Versus Circadian Timed Doxorubicin Plus Cisplatin in Stage III and IV or Recurrent Endometrial Carcinoma: A Gynecologic Oncology Group Study by GALLION, Holly H, BRUNETTO, Virginia L, CIBULL, Michael, LENTZ, Samuel S, REID, Gary, SOPER, John T, BURGER, Robert A, ANDERSEN, Willie

“…To determine if circadian timed (CT) chemotherapy results in improved response, progression-free survival (PFS), overall survival (OS), and lower toxicity,…”
Get full text

A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study by Keys, Henry M, Roberts, James A, Brunetto, Virginia L, Zaino, Richard J, Spirtos, Nick M, Bloss, Jeffrey D, Pearlman, Andrew, Maiman, Mitchell A, Bell, Jeffrey G

“…Background. Despite their low risk for recurrence, many women with endometrial adenocarcinoma receive postoperative radiation therapy (RT). This study was…”
Get full text

Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study by Fiorica, James V, Brunetto, Virginia L, Hanjani, Parviz, Lentz, Samuel S, Mannel, Robert, Andersen, Willie

“…Objectives. To estimate the objective response rate and toxicity associated with alternating megestrol acetate (MA) and tamoxifen citrate (T) in women with…”
Get full text

Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study by Whitney, Charles W, Brunetto, Virginia L, Zaino, Richard J, Lentz, Samuel S, Sorosky, Joel, Armstrong, Deborah K, Lee, Roger B

“…Objectives. The objectives of this study were to estimate the clinical response rate and toxicity of daily tamoxifen combined with intermittent weekly…”
Get full text

A Phase III Trial of Ifosfamide with or without Cisplatin in Carcinosarcoma of the Uterus: A Gynecologic Oncology Group Study by Sutton, Gregory, Brunetto, Virginia L., Kilgore, Larry, Soper, John T., McGehee, Ramon, Olt, George, Lentz, Samuel S., Sorosky, Joel, Hsiu, Jeng-Gwang

“…Objective. The aims of this study were to substantiate the previously reported activity of ifosfamide in patients with advanced, persistent, or recurrent…”
Get full text

A Phase II Trial of Anastrozole in Advanced Recurrent or Persistent Endometrial Carcinoma: A Gynecologic Oncology Group Study by Rose, Peter G., Brunetto, Virginia L., VanLe, Linda, Bell, Jeffrey, Walker, Joan L., Lee, Roger B.

“…Background. Some endometrial cancers are hormonally dependent. A principal source of circulating estrogen is conversion of adrenal androstenedione by…”
Get full text

Goserelin acetate as treatment for recurrent endometrial carcinoma: A Gynecologic Oncology Group study by ASBURY, Robert F, BRUNETTO, Virginia L, LEE, Roger B, REID, Gary, ROCERETO, Thomas F

“…This Gynecologic Oncology Group (GOG) study was designed to estimate the activity of goserelin acetate as treatment for advanced and recurrent endometrial…”
Get full text

Phase II trial of danazol in advanced, recurrent, or persistent endometrial cancer: a Gynecologic Oncology Group study by Covens, Allan, Brunetto, Virginia L, Markman, Maurie, Orr, James W, Lentz, Samuel S, Benda, Jo

“…Objectives. To evaluate the activity and toxicity of danazol in advanced, recurrent, or persistent endometrial carcinoma. Methods. Eligible patients with…”
Get full text

A Phase III Trial of Surgery With or Without Adjunctive External Pelvic Radiation Therapy in Intermediate-Risk Endometrial Adenocarcinoma: A Gynecologic Oncology Group Study by Keys, Henry M, Roberts, James A, Brunetto, Virginia L, Zaino, Richard J, Spirtos, Nick M, Bloss, Jeffrey D, Pearlman, Andrew, Maiman, Mitchell A, Bell, Jeffrey G

“…Between June 1987 and July 1995, 448 women with endometrial cancer were enrolled in a prospective, randomized trial comparing the use of postoperative…”
Get full text

DNA content is an independent prognostic indicator in endometrial adenocarcinoma. A Gynecologic Oncology Group study by Zaino, R J, Davis, A T, Ohlsson-Wilhelm, B M, Brunetto, V L

“…The identification of prognostic variables is an important aspect of managing and counseling women with endometrial adenocarcinoma. The surgical stage, age,…”
Get more information

An Analysis of Cell Type in Patients with Surgically Staged Stage IB Carcinoma of the Cervix: A Gynecologic Oncology Group Study by Look, Katherine Y., Brunetto, Virginia L., Clarke-Pearson, Daniel L., Averette, Hervy E., Major, Francis J., Alvarez, Ronald D., Homesley, Howard D., Zaino, Richard J.

“…The influence of cell type on recurrence-free interval (RFI) and survival after radical hysterectomy for patients with Stage IB carcinoma of the cervix was…”
Get full text

Erratum to “A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study” [Gynecol. Oncol. 92 (2004) 744–751] by Keys, Henry M, Roberts, James A, Brunetto, Virginia L, Zaino, Richard J, Spirtos, Nick M, Bloss, Jeffrey D, Pearlman, Andrew, Maiman, Mitchell A, Bell, Jeffrey G

Get full text

Villoglandular adenocarcinoma of the endometrium : A clinicopathologic Study of 61 cases : A gynecologic oncology Group Study by ZAINO, R. J, KURMAN, R. J, BRUNETTO, V. L, MORROW, C. P, BENTLEY, R. C, CAPPELLARI, J. O, BITTERMAN, P

“…Papillary endometrioid or villoglandular adenocarcinoma (VGA) is a relatively common type of endometrial adenocarcinoma, but studies describing its behavior…”
Get full text

In Reply by Gallion, Holly H., Brunetto (Filiaci), Virginia L.

Get full text

Secondary Cytoreductive Surgery at Second-Look Laparotomy in Advanced Ovarian Cancer: A Gynecologic Oncology Group Study by Williams, Laura, Brunetto, Virginia L., Yordan, Edgardo, DiSaia, Philip J., Creasman, William T.

“…Reports which analyzed the effects of secondary cytoreductive surgery at second-look laparotomy have often included small numbers of patients who have been…”
Get full text

Phenotypic Markers and BCL-1 Gene Rearrangements in B-Cell Chronic Lymphocytic Leukemia: A Cancer and Leukemia Group B Study by Newman, Roland A., Peterson, Bercedis, Davey, Frederick R., Brabyn, Clodagh, Collins, Heli, Brunetto, Virginia L., Duggan, David B., Weiss, Raymond B., Royston, Ivor, Millard, Frederick E., Miller, Antonius A., Bloomfield, Clara D.

“…The markers, CD11 b, CD11 c, CD14, CD21, CD23, CD25, CD38, and FMC7 were correlated with morphologic and other laboratory and clinical characteristics of 127…”
Get full text

Biological Effects of Recombinant Human Granulocyte Colony-Stimulating Factor in Patients With Untreated Acute Myeloid Leukemia by Baer, Maria R., Bernstein, Steven H., Brunetto, Virginia L., Heinonen, Kristiina, Mrózek, Krzysztof, Swann, Victoria L., Minderman, Hans, Block, AnneMarie W., Pixley, Lynda A., Christiansen, Neal P., Fay, Joseph W., Barcos, Maurice, Rustum, Youcef, Herzig, Geoffrey P., Bloomfield, Clara D.

“…Hematopoietic growth factors are being administered to patients with acute myeloid leukemia (AMD both to shorten the duration of chemotherapy-induced…”
Get full text